Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1956 3
1957 1
1958 4
1959 3
1960 3
1961 4
1962 3
1963 2
1966 4
1967 5
1970 2
1971 1
1973 4
1974 1
1975 2
1976 5
1977 7
1978 3
1979 5
1980 3
1981 2
1982 5
1984 5
1985 1
1986 3
1987 6
1988 6
1989 5
1990 4
1991 8
1992 10
1993 15
1994 6
1995 9
1996 11
1997 14
1998 10
1999 7
2000 6
2001 7
2002 6
2003 8
2004 2
2005 5
2006 5
2007 7
2008 3
2009 2
2010 5
2011 7
2012 7
2013 9
2014 8
2015 7
2016 11
2017 13
2018 12
2019 9
2020 13
2021 23
2022 15
2023 16
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

368 results

Results by year

Filters applied: . Clear all
Page 1
A Randomized, Controlled Trial of Liraglutide for Adolescents with Obesity.
Kelly AS, Auerbach P, Barrientos-Perez M, Gies I, Hale PM, Marcus C, Mastrandrea LD, Prabhu N, Arslanian S; NN8022-4180 Trial Investigators. Kelly AS, et al. N Engl J Med. 2020 May 28;382(22):2117-2128. doi: 10.1056/NEJMoa1916038. Epub 2020 Mar 31. N Engl J Med. 2020. PMID: 32233338 Clinical Trial.
Regulation of growth hormone-binding protein.
Massa GG. Massa GG. Acta Paediatr Suppl. 1996 Oct;417:102-4. doi: 10.1111/j.1651-2227.1996.tb14313.x. Acta Paediatr Suppl. 1996. PMID: 9055927 Review. No abstract available.
STYLE (NCT03449173): A Phase 2 Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines.
Proto C, Manglaviti S, Lo Russo G, Musca M, Galli G, Imbimbo M, Perrino M, Cordua N, Rulli E, Ballatore Z, Maso AD, Chella A, Sbrana A, Prelaj A, Ferrara R, Occhipinti M, Brambilla M, De Toma A, Mazzeo L, Beninato T, Signorelli D, Massa G, Greco FG, Calareso G, Miliziano D, Di Mauro RM, Mella G, Lucarelli A, Paggio A, Galli F, Torri V, de Braud FGM, Pasello G, Petrini I, Berardi R, Ganzinelli M, Garassino MC, Zucali PA. Proto C, et al. Among authors: massa g. J Thorac Oncol. 2023 Aug;18(8):1070-1081. doi: 10.1016/j.jtho.2023.04.009. Epub 2023 Apr 23. J Thorac Oncol. 2023. PMID: 37094664 Clinical Trial.
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression.
Prelaj A, Pircher CC, Massa G, Martelli V, Corrao G, Lo Russo G, Proto C, Ferrara R, Galli G, De Toma A, Genova C, Jereczek-Fossa BA, Braud F, Garassino MC, Rebuzzi SE. Prelaj A, et al. Among authors: massa g. Cancers (Basel). 2021 Mar 15;13(6):1300. doi: 10.3390/cancers13061300. Cancers (Basel). 2021. PMID: 33803958 Free PMC article. Review.
Pralsetinib in RET fusion-positive non-small-cell lung cancer: A real-world data (RWD) analysis from the Italian expanded access program (EAP).
Passaro A, Russo GL, Passiglia F, D'Arcangelo M, Sbrana A, Russano M, Bonanno L, Giusti R, Metro G, Bertolini F, Grisanti S, Carta A, Cecere F, Montrone M, Massa G, Perrone F, Simionato F, Guaitoli G, Scotti V, Genova C, Lugini A, Bonomi L, Attili I, de Marinis F. Passaro A, et al. Among authors: massa g. Lung Cancer. 2022 Dec;174:118-124. doi: 10.1016/j.lungcan.2022.11.005. Epub 2022 Nov 9. Lung Cancer. 2022. PMID: 36379124
368 results